Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Open in API
Filings indexed 1,061 across all filing types
Latest filing 2022-04-21 Board/Management Inform…
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on amendments to agreements with the company's CEO, including stock option vesting schedules and employment terms. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The primary subject is changes in management agreements and compensatory arrangements, specifically related to the CEO. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members. The document length is over 11,000 characters, indicating it is a full filing, not just a brief announcement or certification. Therefore, the correct classification is MANG with high confidence.
2022-04-21 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is under Item 5.02, which details the departure of a director from the company's board. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is not a full annual report, audit report, or earnings release, but a specific announcement about management changes. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is 3183 characters, which is consistent with a typical 8-K filing for such an event, not a full report.
2022-04-06 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.